bluebird bio, Inc. (bluebird) has announced the filing of a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The proxy statement includes several key proposals requiring stockholder approval, including amendments to the company's Amended and Restated Certificate of Incorporation to provide for the exculpation of officers for certain breaches of fiduciary duty, a reverse stock split of common stock at a ratio between 1-for-15 and 1-for-20, and the amendment and restatement of the 2023 Incentive Award Plan to increase the number of shares authorized for issuance. The meeting is scheduled for November 6, 2024, at bluebird's offices in Somerville, Massachusetts. Stockholders as of the record date, September 16, 2024, are entitled to vote. The proposals aim to maintain compliance with NASDAQ's minimum bid price requirement, enhance capital raising capabilities, and ensure competitive equity awards for employee retention and motivation.

bluebird bio, Inc. (bluebird) has announced the filing of a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The proxy statement includes several key proposals requiring stockholder approval, including amendments to the company's Amended and Restated Certificate of Incorporation to provide for the exculpation of officers for certain breaches of fiduciary duty, a reverse stock split of common stock at a ratio between 1-for-15 and 1-for-20, and the amendment and restatement of the 2023 Incentive Award Plan to increase the number of shares authorized for issuance. The meeting is scheduled for November 6, 2024, at bluebird's offices in Somerville, Massachusetts. Stockholders as of the record date, September 16, 2024, are entitled to vote. The proposals aim to maintain compliance with NASDAQ's minimum bid price requirement, enhance capital raising capabilities, and ensure competitive equity awards for employee retention and motivation.